• HOME
    • WHO WE ARE
    • VISION SCIENCE
  • ABOUT
    • WHAT WE BELIEVE
    • ORIENTATION
    • OUR BUSINESS
    • BRAND INDENTITY
  • TEAM
    • TEAM
    • ADVISORY BOD
  • PORTFOLIO
    • VENTURE CAPITAL
    • INDUSTRY INVESTMENT
    • INCUBATION
    • PORTFOLIO LITERATURE
  • RIMONCI INDEX
  • RESPECT
  • NEWS
    • INDUSTRY UPDATE
    • RIMONCI IN THE NEWS
  • CONTACT
  • LP Center
  • 中文
  • EN
  • Log in
  • Register
Log out
넳 넲

INDUSTRY UPDATE

  • 2020-12-18

    Number of FDA new molecular entity approvals in 2020 similar to 2019

    Despite the COVID19 pandemic, the FDA 
    approved 47 new molecular entities in 2020
    including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

    more >

  • 2020-12-07

    Cornea Products Market to Grow an Estimated 6.1 Percent Through 2025

    Market Scope’s “2020 Cornea Products Market 
    Report” was published in November

    more >

  • 2020-11-20

    Inspecs Announces Acquisition of Eschenbach

    Inspecs Group,  a leading designer, manufacturer
    and distributor of eyewear frames, announced that 
    it has conditionally agreed to acquire all of the equity interests in Eschenbach Holding GmbH for €94.85 million (approximately £84.7 million).

    more >

  • 2020-11-10

    SLT as primary glaucoma treatment may offer reduced cost, better efficacy than eye drops

    “With SLT laser, you simply treat the patient, 
    and the rest is history” Nathan Radcliffe, MD

    more >

  • 2020-10-16

    Japanese hospital conducts world's 1st iPS transplant of visual cells

    A Japanese hospital said it has performed the 
    world's first clinical trial of a transplant of visual cells 
    derived from induced pluripotent stem cells, or iPS cells, to treat a patient with pigmentary retinal degeneration.

    more >

  • 2020-09-30

    WVU and Pitt team up for laser trial to treat glaucoma

    Dr. Tony Realini, professor of ophthalmology and glaucoma
    specialist at WVU, will be the principal investigator of
    a $15.2 million study on how a treatment called selective laser trabeculoplasty (SLT).

    more >

RIMONCI IN THE NEWS

  • A New Type of Corneal Availability

    Off-the-shelf, the artificial endothelial 
    implant EndoArt® aims to eliminate the need 
    for donor tissue in corneal edema treatment.

    2020-09-10

  • Patients communication co EyeControl raises $10m

    Israeli startup EyeControl,  announced
    it has closed a Series A round of funding securing over $10 million.

    2020-08-12

  • NovaSight Closes $8M Series A Financing in Quest to Combat Vision Disorders Worldwide

    The round was led by Rimonci Capital
    and joined by world leading strategic 
    investors from both pharmaceutical and medical device industries. Prior to this round the company raised $8M for a total of $16M.

    2020-07-31

  • VISION ON CLOUD, Forum 5

    Introduced neuro protection pathways and
    challenges in ophthalmology fields by the top 
    ophthalmologists, neurologist, management team from multi-national companies.

    2020-07-22

Address: WeWork, 17th Floor, Sony Plaza A, No.16 South Guangshun Street, Chaoyang District, Beijing, China (100015)

© 2020 YUE ICP备19003617号

  • 끅
    • 客服电话

    • 88888888
  • 뀩
    • QQ客服
  • 뀥
    • 服务时间

    • 周一至周五 9:00-18:00
  • 낃
    • 微信二维码

  • 녕
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6